Clinical trials: Vascular Disease，Peripheral
Diabetic Foot, Peripheral Arterial Disease
Microwave Radiometry Thermometry for the Diagnosis of Critical Limb Ischemia in Diabetic Patients
Diagnosis of vascular involvement in diabetic foot disease remains challenging. Differential diagnosis between pure neuropathic or neuro-ischemic diabetic foot requires a combination of clinical examination, medical history and…
- Conditions
- Diabetic Foot, Peripheral Arterial Disease, Ischaemic Neuropathy
- Trial name
- NCT03002116
- Testing
- Tissue thermometry using non-invasive microwave radiometry device
- Where
- 3 sites in Greece, United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Attikon Hospital
Peripheral Arterial Disease
Hemodynamic Characteristics of Peripheral Arterial Disease Using Computational Fluid Dynamics
Peripheral arterial disease can reduce blood flow to the legs. This study will examine how blood flow patterns in the leg arteries differ between people with peripheral arterial disease and people without the disease.
- Trial name
- NCT07860138
- Testing
- Computational Fluid Dynamics Simulation
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Fudan University
Critical Limb Ischemia (CLI)
Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System
This is a prospective, double-blinded, randomized, placebo-controlled, multi-center, pivotal clinical study in which subjects are evaluated for prevention of major limb amputation in the treatment of non-reconstructable…
- Trial name
- CLIRST III (NCT02538978)
- Testing
- Autologous Bone Marrow Concentrate (aBMC)
- Volunteers
- 224 people
- Sponsor
- Cesca Therapeutics, Inc.
Peripheral Arterial Disease
The Effects of Omega-3 Fatty Acids on Peripheral Arterial Disease II
Investigators hypothesize that high-dose n-3 polyunsaturated fatty acids (PUFA) oral supplementation will improve systemic inflammation, vascular function, and symptomatic status of patients with PAD.
- Trial name
- OMEGA-PAD II (NCT01979874)
- Testing
- Pro-Omega
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Francisco
Critical Limb Ischemia, Buerger Disease
Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)
A prospective, open label, controlled, randomized, double arm, multi-center study to assess the efficacy and safety of CLBS12 in patients with critical limb ischemia (CLI) due to arteriosclerosis obliterans (ASO) with a single…
- Conditions
- Critical Limb Ischemia, Buerger Disease, Thromboangiitis Obliterans, Atherosclerosis Obliterans
- Trial name
- NCT02501018
- Testing
- CLBS12, SOC
- Where
- 12 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Lisata Therapeutics, Inc.
Peripheral Arterial Disease
Cardiac Remote Ischemic Preconditioning Before Elective Major Vascular Surgery
Vascular surgery is considered a high-risk operation with an anticipated risk of major cardiovascular complications in excess of 5%.
- Trial name
- CRIPES (NCT01403337)
- Testing
- Ischemic preconditioning, Control
- Where
- United States
- Volunteers
- 205 people
- Sponsor
- Center for Veterans Research and Education
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD)
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
The study will explore the impact of photobiomodulation (PBM), pulsating at frequencies of red (660nm) and near-infrared (810nm)(NIR), concurrent with a ketogenic dietary protocol (serum ketones @ .5 - 2.0 mmol/L) to mediate…
- Conditions
- Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
- Trial name
- NCT03859245
- Testing
- Photobiomodulation, Ketogenic diet
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Peripheral Vascular Diseases
GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)
The objective of the study is collect data on the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in the treatment of chronic Superficial Femoral Artery disease. Device patency at 12 months is the primary endpoint.
- Trial name
- VIPER (NCT00541307)
- Testing
- Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
- Where
- 5 sites in United States
- Volunteers
- 119 people
- Sponsor
- W.L.Gore & Associates
Limb Salvage Rates With Endovascular Therapy
Endovascular Limb Salvage in Trinidad and Tobago
The purpose of this study was to investigate limb salvage rates in patients with critical limb ischemia after endovascular revascularization.
- Trial name
- NCT05547022
- Testing
- Endovascular revascularisation
- Where
- Trinidad and Tobago
- Volunteers
- 157 people
- Sponsor
- Naveen Seecheran
Intermittent Claudication, Ischemia Vascular
Ischemic Preconditioning Claudication Study
This study proposes ischemic preconditioning (IPC) as a novel intervention to improve walking distance in patients with intermittent claudication.
- Conditions
- Intermittent Claudication, Ischemia Vascular, Peripheral Arterial Disease, Peripheral Vascular Disease
- Trial name
- NCT03511157
- Testing
- Ischemic Preconditioning, Control Group
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Medical College of Wisconsin
Spinal Lumbar Stenosis, Claudication, Intermittent
Evaluation of Safety and Effectiveness of Lobster Dynamic Interspinous Spacer in Lumbar Spinal Stenosis
The aim of this study is to demonstrate the safety and effectiveness of the Lobster interspinous spacer device for the treatment of Lumbar Spinal Stenosis in comparison to an SSED-based performance goal.
- Trial name
- LB2CT01 (NCT05587465)
- Testing
- Lobster Device
- Where
- Italy
- Volunteers
- 210 people
- Sponsor
- Diametros Medical srl
Baroreflex Failure Syndrome, Hypertension, Resistant to Conventional Therapy
UK Registry for Baroreflex Activation Therapy
This study is a post-marketing open label single arm, single centre clinical trial of electrical carotid sinus stimulation with the Barostim Neo device to target sub-optimally controlled arterial hypertension or highly variable…
- Trial name
- UK-BAT (NCT03730519)
- Testing
- Baroreflex Activation Therapy with Barostim Neo
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Queen Mary University of London
Stroke
NEURO-MODULATORY EFFECT OF ELECTRO-ACUPUNCTURE ON COMPLEX REGIONAL PAIN SYNDROME IN POST STROKE PATIENTS
Improvement in pain and range of motion (ROM) outcomes for stroke cases suffering from complex regional pain syndrome (CRPS) can be attained through Electro-acupuncture therapy, which in turn improve functional independence and…
- Trial name
- NCT07869667
- Testing
- Electroacupuncture, Conventional physical therapy program
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Ahmed Alshimy
Multiple Myeloma, Peripheral Neuropathy Due to Chemotherapy
Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical Research
The goal of this study is to find out if taking fish oil by mouth can help prevent or lessen a side effect called peripheral neuropathy in patients who are being treated with the chemotherapy drug bortezomib.
- Trial name
- NCT07403071
- Testing
- Fish Oil (Containing Omega-3 Acids)
- Volunteers
- 200 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
PAD, Critical Limb Ischemia
Treatment of No-option CLI by G-CSF-mobilized PB-MNC
This study will investigate the efficacy of G-CSF mobilized mononuclear cell injection of patients with PAD who presented with no-option CLI.
- Conditions
- PAD, Critical Limb Ischemia, Atherosclerotic Ischemic Disease
- Trial name
- NCT03686228
- Testing
- PB-MNC therapy, No-PB-MNC therapy
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Mahidol University
Refractory Cancer, Refractory Neoplasm
9-ING-41 in Pediatric Patients With Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor
- Trial name
- NCT04239092
- Testing
- 9-ING-41, Irinotecan, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Actuate Therapeutics Inc.
Peripheral Artery Disease
BIOTRONIK Dynetic-35 Stent for the Treatment of Peripheral Iliac Lesions
BIOTRONIK cobalt chromium balloon-expandable Dynetic-35 stent in association with Passeo-35 Xeo peripheral dilation catheter for the treatment of peripheral iliac lesions
- Trial name
- BIONETIC-I (NCT04830228)
- Testing
- Ballon expandable stent and PTA
- Where
- 15 sites in Austria, Belgium and 4 more
- Volunteers
- 160 people
- Sponsor
- Biotronik AG
Peripheral Arterial Disease, Claudication
VISIBILITY™ Iliac Study
The VISIBILITY Iliac study is a prospective, multi-center, non-randomized study confirming the safety and effectiveness of stenting using the Visi-Pro™ Balloon Expandable Stent System for the treatment of stenotic, restenotic or…
- Trial name
- NCT01402700
- Testing
- Visi-Pro™ Balloon Expandable Stent System
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Medtronic Endovascular
Peripheral Vascular Diseases
ASSESS Study: Evaluation of ABSOLUTE™ Stent System for Occluded Arteries
The purpose of this study is to investigate the performance of the ABSOLUTE™ .035 peripheral self-expanding stent system in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries.
- Trial name
- NCT00180505
- Testing
- ABSOLUTE™: Self-Expandable Peripheral Nitinol Stent
- Where
- 13 sites in Austria, Belgium and 5 more
- Volunteers
- 120 people
- Sponsor
- Abbott Medical Devices
Xerosis Cutis, Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Effectiveness of CBD for Neuropathic Pain in Diabetic Foot Neuropathy
Evaluation of cannabidiol and urea 10%.
- Trial name
- NCT07162454
- Testing
- Group 1. Complete formula, Group 2. Cannabidiol and Urea 10% formula.
- Where
- Spain
- Volunteers
- 23 people
- Sponsor
- Universidad Complutense de Madrid
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.